Our Research (possibly logo-themed text)
Cenna's proprietary technology addresses the underlying cause of the disease, the inappropriate deposition of the toxic species, Aß, in the brains of patients with AD. We have developed a novel druggable target and has discovered several lead peptide compounds that are active in vivo.
Our lead candidate P8 inhibits the production of Aß in vitro and in a transgenic mouse model of AD by over 50%, is stable and can be delivered to the brain.
Cenna’s novel technology inhibits the production of Aß by >50%in vitroand in a transgenic mouse model of Alzheimer’s disease Cenna’s approach is different, specific and interferes with only the reaction that produces Aß, as opposed to approaches that target the enzymes responsible for its cleavage from APP, ß- andγ-secretase, which can affect multiple reactions in cells.
Cenna's Drug Candidate
Cenna's first in class drug candidates are small peptides and small molecules. These candidates have been designed to selectively and specifically bind to the APP, inhibiting its processing to A beta. Importantly, our drug candidates do not target or affect the catalytic activities of beta negative or y-secretase. This targeted approach holds promise for the development of effective treatments for Alzheimer's Disease.